International Clinical Trial: Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133947) titled 'Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial' on Oct. 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital of Sichuan University

Condition: Renal Cell Carcinoma

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-10-15

Target Sample Size: Experimental Group:66;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=346578

Disclaimer...